Login to Your Account

Other News To Note

Wednesday, January 18, 2012
• Cellceutix Corp., of Beverly, Mass., said preclinical research into the mechanism of action of Kevetrin showed that the drug not only activates p53 but targets HDAC2. Kevetrin down-regulated HDAC2 in mutant and null p53 cancer cell lines. Clinical trials in cancer are expected to start this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription